MAZE THERAPEUTICS, INC. (MAZE) Debt / Equity
- 2026-06-30: Debt/Equity Ratio 0.09.
- 2026-03-31: Debt/Equity Ratio 0.11.
Complete source-backed debt/equity ratio history.
- Available history
- 2026-03-31 to 2026-06-30
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2026-06-30 | 0.09 |
| 2026-03-31 | 0.11 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |